Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: a proof-of-concept study
Open accessAbstract
Background: Mesenchymal Consensus Molecular Subtype 4 (CMS4) colon cancer is associated with poor prognosis and therapy resistance. In this proof-of-concept study, we assessed whether a rationally chosen drug could mitigate the distinguishing molecular features of primary CMS4 colon cancer. Methods: In the ImPACCT trial, informed consent was obtained for molecular subtyping at initial diagnosis of colon cancer using a validated RT-qPCR CMS4-test on three biopsies per tumor (Phase-1, n=69 patients), and for neoadjuvant CMS4-targeting therapy with imatinib (Phase-2, n=5). Pre- and post-treatment tumor biopsies were analyzed by RNA-sequencing and immunohistochemistry. Imatinib-induced gene expression changes were associated with molecular subtypes and survival in an independent cohort of 3232 primary colon cancer. Results: The CMS4-test classified 52/172 biopsies as CMS4 (30%). Five patients consented to imatinib treatment prior to surgery, yielding 15 pre- and 15 post-treatment samples for molecular analysis. Imatinib treatment caused significant suppression of mesenchymal genes and upregulation of genes encoding epithelial junctions. The gene expression changes induced by imatinib were associated with improved survival and a shift from CMS4 to CMS2. Conclusion: Imatinib may have value as a CMS-switching drug in primary colon cancer and induces a gene expression program that is associated with improved survival.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Imatinib suppresses mesenchymal genes in posttreatment samples from 5 patients with primary CMS4 colorectal cancer who consented to treatment prior to surgery.
“| PDGF pathway | Imatinib | Suppression of mesenchymal genes in posttreatment samples (n = 5 patients with primary CMS4 colorectal cancer who consented to treatment prior to surgery) | (63) |”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [63]
Positive responses have been reported for CMS4 patients treated with imatinib before surgery, in a very limited number of patients.
“positive responses have been reported for CMS4 patients treated with (i) imatinib—targeting the PDGF pathway—before surgery (ImPACCT trial), however in a very limited number of patients (63)”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · see citing works
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807 · see citing works
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908 · see citing works
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499 · see citing works
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · see citing works
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M. J., Obenauf, A. C., Angell, H. K., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,390 · see citing works
KEGG: integrating viruses and cellular organisms
Kanehisa, M. I., Furumichi, M., Sato, Y., Ishiguro-Watanabe, M., & Tanabe, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa970 · Cited by 4,042 · see citing works
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
Aceto, N., Bardia, A., Miyamoto, D. T., Collier, M. D., Wittner, B. S., Spencer, J. A., Yu, M., Pely, A., Engstrom, A., Zhu, H., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.013 · Cited by 2,438 · see citing works
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409 · cited 2× · see citing works
“By applying a dataset of quantitative dissociation constants (Kd) of drug-target interactions for 72 distinct kinase inhibitors (26) a list of candidate CMS4-targeting TKIs was identified containing six FDA-approved anti-cancer drugs (Supplementary Table S4).”
MethodMarisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001453 · Cited by 1,507 · see citing works
Stromal gene expression defines poor-prognosis subtypes in colorectal cancer
Calon, A., Lonardo, E., Berenguer-Llergo, A., Espinet, E., Hernando-Momblona, X., Iglesias, M., Sevillano, M., Palomo-Ponce, S., Tauriello, D. V. F., Byrom, D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3225 · Cited by 1,070 · see citing works
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. M. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.126 · Cited by 1,038 · see citing works
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
Magnuson, B., Ekim, B., & Fingar, D. C. (2012) · Biochemical Journal · doi:10.1042/bj20110892 · Cited by 1,015 · see citing works
Stromal contribution to the colorectal cancer transcriptome
Isella, C., Terrasi, A., Bellomo, S. E., Petti, C., Galatola, G., Muratore, A., Mellano, A., Senetta, R., Cassenti, A., Sonetto, C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3224 · Cited by 640 · see citing works
The Intestinal Wnt/TCF Signature
van der Flier, L. G., Sabates–Bellver, J., Oving, I. M., Haegebarth, A., de Palo, M., Anti, M., van Gijn, M. E., Suijkerbuijk, S. J. E., van de Wetering, M., Marra, G., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.039 · Cited by 514 · see citing works
Melo, F. D. S. E., Çolak, S., Buikhuisen, J. Y., Köster, J., Cameron, K., de Jong, J. H., Tuynman, J. B., Prasetyanti, P. R., Fessler, E., van den Bergh, S., et al. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.10.008 · Cited by 333 · see citing works
mTORC1-mediated translational elongation limits intestinal tumour initiation and growth
Faller, W. J., Jackson, T. J., Knight, J. R. P., Ridgway, R. A., Jamieson, T. J., Karim, S. A., Jones, C., Radulescu, S., Huels, D. J., Myant, K., et al. (2014) · Nature · doi:10.1038/nature13896 · Cited by 302 · see citing works
Sirinukunwattana, K., Domingo, E., Richman, S. D., Redmond, K. L., Blake, A., Verrill, C., Leedham, S. J., Chatzipli, A., Hardy, C., Whalley, C. M., et al. (2021) · Gut · doi:10.1136/gutjnl-2019-319866 · Cited by 264 · cited 1× · see citing works
“Several tissue-based diagnostic tools have been developed for clinical CMS stratification (2, 9, 51, 52).”
MethodCompensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
Burchert, A., Wang, Y., Cai, D., von Bubnoff, N. C. C., Paschka, P., Müller‐Brüsselbach, S., Ottmann, O. G., Duyster, J., Hochhaus, A., & Neubauer, A. (2005) · Leukemia · doi:10.1038/sj.leu.2403898 · Cited by 212 · see citing works
ten Hoorn, S., de Back, T. R., Sommeijer, D. W., & Vermeulen, L. (2022) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab106 · Cited by 203 · see citing works
Trinh, A., Trumpi, K., De Sousa E Melo, F., Wang, X., de Jong, J. H., Fessler, E., Kuppen, P. J. K., Reimers, M. S., Swets, M., Koopman, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0680 · Cited by 180 · see citing works
Self-citationSong, N., Pogue–Geile, K. L., Gavin, P. G., Yothers, G., Kim, S. R., Johnson, N. L., Lipchik, C., Allegra, C. J., Petrelli, N. J., O’Connell, M. J., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2314 · Cited by 172 · see citing works
The expanding role of mTOR in cancer cell growth and proliferation
Cargnello, M., Tcherkezian, J., & Roux, P. P. (2015) · Mutagenesis · doi:10.1093/mutage/geu045 · Cited by 168 · see citing works
Dunne, P. D., McArt, D. G., Bradley, C. A., O’Reilly, P. G., Barrett, H. L., Cummins, R., O’Grady, T., Arthur, K., Loughrey, M. B., Allen, W. L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0032 · Cited by 162 · see citing works
Schöffski, P., Reichardt, P., Blay, J., Dumez, H., Morgan, J. A., Ray-Coquard, I., Hollaender, N., Jappe, A., & Demetri, G. D. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq076 · Cited by 141 · see citing works
Evdokimova, V. E., Tognon, C. E., Ng, T., & Sorensen, P. H. B. (2009) · Cell Cycle · doi:10.4161/cc.8.18.9537 · Cited by 133 · see citing works
The ever-evolving role of mTOR in translation
Fonseca, B. D., Smith, E. M., Yelle, N., Alain, T., Bushell, M., & Pause, A. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.09.014 · Cited by 105 · see citing works
To “Grow” or “Go”: TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN
Shiwarski, D. J., Shao, C., Bill, A., Kim, J., Xiao, D., Bertrand, C. A., Seethala, R. S., Sano, D., Myers, J. N., Ha, P. K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0363 · Cited by 105 · see citing works
Kitadai, Y., Sasaki, T., Kuwai, T., Nakamura, T., Bucana, C. D., & Fidler, I. J. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060653 · Cited by 104 · see citing works
PDGFRB Promotes Liver Metastasis Formation of Mesenchymal-Like Colorectal Tumor Cells
Steller, E. J. A., Raats, D., Köster, J., Rutten, B., Govaert, K. M., Emmink, B. L., Snoeren, N., van Hooff, S. R., Holstege, F. C. P., Maas, C., et al. (2013) · Neoplasia · doi:10.1593/neo.121726 · Cited by 101 · see citing works
Self-citationDifferentiated Human Colorectal Cancer Cells Protect Tumor-Initiating Cells From Irinotecan
Emmink, B. L., van Houdt, W. J., Vries, R. G. J., Hoogwater, F. J. H., Govaert, K. M., Verheem, A., Nijkamp, M. W., Steller, E. J. A., Jiménez, C. R., Clevers, H. C., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.052 · Cited by 89 · see citing works
Self-citationMetastatic heterogeneity of the consensus molecular subtypes of colorectal cancer
Eide, P. W., Moosavi, S. H., Eilertsen, I. A., Brunsell, T. H., Langerud, J., Berg, K. C. G., Røsok, B. I., Bjørnbeth, B. A., Nesbakken, A., Lothe, R. A., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00223-7 · Cited by 70 · see citing works
Intratumor CMS heterogeneity impacts patient prognosis in localized colon cancer
Marisa, L., Blum, Y., Taieb, J., Ayadi, M., Pilati, C., Le Malicot, K., Lepage, C., Salazar, R., Aust, D., Duval, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0529 · Cited by 68 · see citing works
Singh, P., Kumar, V., Gupta, S. K., Kumari, G., & Verma, M. (2021) · Medical Oncology · doi:10.1007/s12032-021-01462-5 · Cited by 64 · see citing works
Piskol, R., Huw, L., Sergin, I., Kljin, C., Modrusan, Z., Kim, D., Kljavin, N., Tam, R., Patel, R., Burton, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3032 · Cited by 62 · see citing works
Targeting the PDGF Signaling Pathway in the Treatment of Non-Malignant Diseases
Heldin, C. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9484-2 · Cited by 61 · see citing works
Slow proliferation as a biological feature of colorectal cancer metastasis
Anjomshoaa, A., Nasri, S., Humar, B., McCall, J. L., Chatterjee, A., Yoon, H.-S., McNoe, L. A., Black, M. A., & Reeve, A. E. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605229 · Cited by 49 · see citing works
Neoadjuvant chemotherapy affects molecular classification of colorectal tumors
Trumpi, K., Ubink, I., Trinh, A., Djafarihamedani, M., Jongen, J. M., Govaert, K. M., Elias, S. G., van Hooff, S. R., Medema, J. P., Lacle, M. M., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.48 · Cited by 46 · see citing works
Self-citationMarginal association measures for clustered data
Lorenz, D. J., Datta, S., & Harkema, S. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4368 · Cited by 45 · see citing works
Chen, E. C., Karl, T. A., Tomer Kalisky, C., Gupta, S. K., O'Brien, C. A., Longacre, T. A., van de Rijn, M., Quake, S. R., Clarke, M. F., & Rothenberg, M. E. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.042 · Cited by 43 · see citing works
Ubink, I., Elias, S. G., Moelans, C. B., Laclé, M. M., van Grevenstein, W. M. U., van Diest, P. J., Borel Rinkes, I. H. M., & Kranenburg, O. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw303 · Cited by 40 · see citing works
Self-citationLi, J., Dang, Y., Gao, J., Li, Y., Zou, J., & Shen, L. (2015) · Medical Oncology · doi:10.1007/s12032-015-0554-6 · Cited by 40 · see citing works
Fátrai, S., van Schelven, S. J., Ubink, I., Govaert, K. M., Raats, D., Köster, J., Verheem, A., Rinkes, I. H. M. B., & Kranenburg, O. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.003 · Cited by 37 · see citing works
Self-citationStrating, E., Wassenaar, E., Verhagen, M., Rauwerdink, P., van Schelven, S., de Hingh, I., Rinkes, I. B., Boerma, D., Witkamp, A., Lacle, M., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01748-z · Cited by 36 · see citing works
Self-citationNehoff, H. L., Parayath, N. N., McConnell, M. J., Taurin, S., & Greish, K. F. (2015) · Oncotarget · doi:10.18632/oncotarget.5698 · Cited by 34 · see citing works
Schlicker, A., Ellappalayam, A., Beumer, I. J., Snel, M. H. J., Mittempergher, L., Diosdado, B., Dreezen, C., Tian, S., Salazar, R., Loupakis, F., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33003 · Cited by 25 · see citing works
Thomas, L. W., Esposito, C., Stephen, J. M., Costa, A. S. H., Frezza, C., Blacker, T. S., Szabadkai, G., & Ashcroft, M. A. (2019) · Cancer & Metabolism · doi:10.1186/s40170-019-0200-4 · Cited by 25 · see citing works
Hoehler, T., von Wichert, G., Schimanski, C. C., Kanzler, S., Moehler, M. H., Hinke, A., Seufferlein, T. T. W., Siebler, J., Hochhaus, A., Arnold, D., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.409 · Cited by 17 · see citing works
Xing, S., Wang, C., Tang, H., Guo, J., Liu, X., Yi, F., Liu, G., & Wu, X. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.12915 · Cited by 15 · see citing works
Ubink, I., Bloemendal, H. J., Elias, S. G., Brink, M. A., Schwartz, M., Holierhoek, Y. C. W., Verheijen, P. M., Boerman, A. W., Mathijssen, R. H. J., de Leng, W. W. J., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3264-y · Cited by 14 · see citing works
Self-citationMichael, M., Zalcberg, J. R., Gibbs, P., Lipton, L. R., Gouillou, M., Jefford, M., McArthur, G. A., Copeman, M. C., Lynch, K., & Tebbutt, N. C. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2009-5 · Cited by 12 · see citing works
Hou, H., Jia, D., Yan, W., Zhang, X., Wang, C., Li, Y., Chen, H., Huang, W., Li, Z., & Zhang, X. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-637 · Cited by 8 · see citing works
Flagged first, then by citations
1 of the 54 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Mouillet-Richard, S., Cazelles, A., Sroussi, M., Gallois, C., Taieb, J., & Laurent-Puig, P. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3964 · Cited by 43 · see citing works
Targeting the devil: Strategies against cancer-associated fibroblasts in colorectal cancer
Chen, Y., Liang, Z., & Lai, M. (2024) · Translational research · doi:10.1016/j.trsl.2024.04.003 · Cited by 41 · see citing works
Reitsam, N. G., Grozdanov, V., Loeffler, C. M. L., Muti, H. S., Grosser, B., Kather, J. N., & Märkl, B. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00695-y · Cited by 35 · see citing works
Takei, S., Tanaka, Y., Lin, Y.-T., Koyama, S., Fukuoka, S., Hara, H., Nakamura, Y., Kuboki, Y., Kotani, D., Kojima, T., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008210 · Cited by 35 · see citing works
Predictors of response to immunotherapy in colorectal cancer
González‐Montero, J., Rojas, C. I., & Burotto, M. (2024) · The Oncologist · doi:10.1093/oncolo/oyae152 · Cited by 34 · see citing works
Ma, Y., Nenkov, M., Chen, Y., & Gaßler, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158352 · Cited by 28 · see citing works
c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights
Abdellateif, M. S., Bayoumi, A., & Mohammed, M. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s404648 · Cited by 22 · see citing works
Ding, X., Huang, H., Zhang, F., & Jiang, J. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01282-5 · Cited by 21 · see citing works
Reitsam, N. G., Enke, J. S., Trung, K. V., Märkl, B., & Kather, J. N. (2024) · Digestion · doi:10.1159/000539678 · Cited by 22 · see citing works
Kantha, A., Das, D., Pai, E., Kumar, T., & Pandey, M. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04117-1 · Cited by 19 · see citing works
Küçükköse, E., Peters, N. A., Ubink, I., van Keulen, V. A. M., Daghighian, R., Verheem, A., Laoukili, J., & Kranenburg, O. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05078-z · Cited by 18 · see citing works
Self-citationO’Neill, A., Zakaria, N., Egan, H., Corry, S. M., Bull, C., Leonard, N. A., O'Meara, C., Howard, L., Walsh, A., Reidy, E., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012491 · Cited by 14 · see citing works
Tailoring a novel colorectal cancer stem cell-targeted therapy by inhibiting the SMYD3/c-MYC axis
Signorile, M. L., Nicola, E. D., Forte, G., Sanese, P., Fasano, C., Disciglio, V., Marco, K. D., Latrofa, M., Cecco, L. D., Ficorilli, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02290-z · Cited by 14 · see citing works
Biological functions, mechanisms, and clinical significance of circular RNA in colorectal cancer
Fang, G., Xu, D., Zhang, T., Wang, G., Qiu, L., Gao, X., & Miao, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1138481 · Cited by 10 · see citing works
Molecular pathology of colorectal cancer
Noack, P., & Langer, R. (2023) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-023-00893-2 · Cited by 9 · see citing works
Genomic landscape and expression profile of consensus molecular subtype four of colorectal cancer
Lu, Y., Gu, D., Zhao, C., Sun, Y., Li, W., He, L., Wang, X., Kou, Z., Jiang, S., & Guo, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160052 · Cited by 7 · see citing works
Bacteroides fragilis Promotes Mesenchymal Subtype in Colorectal Cancer
Chang, S. Y., Park, J., Park, S. J., Park, J. J., Cheon, J. H., Kim, D.-K., & Kim, T. I. (2025) · Cancers · doi:10.3390/cancers17233822 · Cited by 5 · see citing works
Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer
Strating, E., van de Loo, A., Elias, S. G., Lam, M. G. E. H., & Kranenburg, O. (2023) · PET Clinics · doi:10.1016/j.cpet.2023.02.003 · Cited by 4 · see citing works
Self-citationInterval Colorectal Cancer in Inflammatory Bowel Disease
Cunha, T. D., & Vaziri, H. (2023) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001901 · Cited by 4 · see citing works
González‐Montero, J., Burotto, M., Valenzuela, G., Mateluna, D., Buen-Abad-Torrealba, F., Toro, J., Barajas, O., & Marcelain, K. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i10.409 · Cited by 4 · see citing works
Ruiz‐Malagón, A. J., Rodríguez‐Sojo, M. J., García-García, J., Ho‐Plagaro, A., García, F., Vezza, T., Redondo‐Cerezo, E., Griñán‐Lisón, C., Marchal, J. A., Rodríguez‐Cabezas, M. E., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01629-0 · Cited by 3 · see citing works
Liu, Z., Gu, W., Liu, L., Wu, S., Yao, Z., Sun, Y., Huang, D., & Tong, T. (2026) · Radiology · doi:10.1148/radiol.251719 · Cited by 3 · see citing works
Carmi, I., Orosz, A., Hajdó, S., Zeöld, A., Hegedűs, T., Kelemen-Győri, D., Pozsár, J., Tölgyes, T., & Wiener, Z. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02395-6 · Cited by 2 · see citing works
Reitsam, N. G., Märkl, B., Nagtegaal, I. D., & Svrcek, M. (2026) · Histopathology · doi:10.1111/his.70237 · Cited by 2 · see citing works
Joint Bayesian additive regression trees for multiple nonlinear dependency networks
Huang, L., Peterson, C. B., & Ha, M. J. (2025) · Biometrics · doi:10.1093/biomtc/ujaf158 · Cited by 1 · see citing works
Kinase-targeted therapy in subsets of colorectal cancer
Barila, P. M. G., & Medema, J. P. (2023) · Oncoscience · doi:10.18632/oncoscience.580 · Cited by 1 · see citing works
LAI, Z., ZHAO, H., & Deng, H. X. (2024) · Biocell · doi:10.32604/biocell.2024.053983
Corry, S. M., Sakhnevych, S. S., Mohamed, N. E., Malla, S. B., Byrne, R. M., Young, A., Amirkhah, R., Bull, C., Lees, A., Redmond, K. L., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-10295-9
Vtorushin, S. V., Tarasov, M. N., Владиславовна, П. А., Сергеевич, В. К., Naumov, S. S., & Krakhmal, N. V. (2026) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2025-4-120-131
Non-coding RNA Trojan nanocarriers in CRC: Mechanistic crossroads and therapeutic challenges
Cheng, M., Ni, Y., Zhang, W., & Wu, Q. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119098
Guo, Z., & (405), W. Z. (2026) · Molecular Genetics and Genomics · doi:10.1007/s00438-026-02377-4
CMS4-focused multi-omic integration enhances antigen target identification in colorectal cancerPreprint
Fox, E., Meunier, L., Weill, S., Appé, G., Behdenna, A., Hensen, L., Lafond, C., Nordor, A. V., & Marijon, C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.04.722755
Aguiari, G., Bianchi, N., & Franzese, O. (2026) · Cells · doi:10.3390/cells15121074
Wei, Y., Chu, W., Rao, C., & Yang, Y. (2026) · Medicine · doi:10.1097/md.0000000000050211
van Duijvenvoorde, M., Kranenburg, O., van den Bos, M., Hagendoorn, J., Roodhart, J. M. L., Milne, A. N., Riele, W. W. T., Lange, M. M., Swijnenburg, R., Arensman, R., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-128210
Self-citation
- Authors
- Peters, N. A., Constantinides, A., Ubink, I., van Kuik, J., Bloemendal, H. J., van Dodewaard, J. M., Brink, M. A., Schwartz, T. P., Lolkema, M. P. J. K., Lacle, M. M., Moons, L. M., Geesing, J., van Grevenstein, W. M. U., Roodhart, J. M. L., Koopman, M., Elias, S. G., Borel Rinkes, I. H. M., & Kranenburg, O.
- Affiliations
- Utrecht University (NL)
- Radboud University Medical Center (NL)
- Meander Medisch Centrum (NL)
- Erasmus MC (NL)
- Diakonessenhuis hospital (NL)
- Corresponding author
- Kranenburg, Onno
- ORCID
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2022-09-06
- Volume
- 12
- Pages
- 969855-969855
- ISSN
- 2234-943X (ISSN-L)
- PMC
- PMC9486194
- OpenAlex
- W4294739303
- Cited by
- 35
- References
- 54
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 8 · 2023: 9 · 2022: 1
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- ZonMw (95104001)
- KWF Kankerbestrijding (2014-6617)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- colon cancer, imatinib, neoadjuvant therapy, mesenchymal subtype, epithelial-mesenchymal transition, gene expression changes, survival, molecular subtyping
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
